De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Acasti Pharma Beheer

Beheer criteriumcontroles 0/4

De CEO Acasti Pharma's is Prashant Kohli, benoemd in Apr2023, heeft een ambtstermijn van 1.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 987.63K, bestaande uit 40.5% salaris en 59.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.21% van de aandelen van het bedrijf, ter waarde $ 64.07K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.4 jaar en 1.3 jaar.

Belangrijke informatie

Prashant Kohli

Algemeen directeur

US$987.6k

Totale compensatie

Percentage CEO-salaris	40.5%
Dienstverband CEO	1.5yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	1.4yrs
Gemiddelde ambtstermijn bestuur	1.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Prashant Kohli's beloning veranderd ten opzichte van Acasti Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$11m
Mar 31 2024	US$988k	US$400k	-US$13m
Dec 31 2023	n/a	n/a	-US$39m
Sep 30 2023	n/a	n/a	-US$40m
Jun 30 2023	n/a	n/a	-US$42m
Mar 31 2023	US$512k	US$379k	-US$42m
Dec 31 2022	n/a	n/a	-US$17m
Sep 30 2022	n/a	n/a	-US$17m
Jun 30 2022	n/a	n/a	-US$11m
Mar 31 2022	US$655k	US$141k	-US$10m

Compensatie versus markt: De totale vergoeding ($USD 987.63K ) Prashant } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Prashant is gestegen terwijl het bedrijf verliesgevend is.

CEO

Prashant Kohli (52 yo)

1.5yrs

Tenure

US$987,630

Compensatie

Mr. Prashant Kohli was Vice President of Commercial Operations at Grace Therapeutics, Inc. He served as Chief Commercial Officer at Acasti Pharma Inc. since 2022 until April 04, 2023, and serves as its Chi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Prashant Kohli	CEO & Director	1.5yrs	US$987.63k	0.21% $ 64.3k
Amresh Kumar	VP of Program Management	1.4yrs	US$405.75k	0.11% $ 33.5k
Carrie D'Andrea	VP of Clinical Operations	1.4yrs	US$411.30k	0% $ 0
Robert DelAversano	VP of Finance and Principal Financial & Accounting Officer	less than a year	geen gegevens	geen gegevens
R. MacDonald	Member of Scientific Advisory Board & Chief Medical Officer	1.4yrs	geen gegevens	geen gegevens

1.4yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ACST wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.4 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Prashant Kohli	CEO & Director	less than a year	US$987.63k	0.21% $ 64.3k
R. MacDonald	Member of Scientific Advisory Board & Chief Medical Officer	2.4yrs	geen gegevens	geen gegevens
Edward Neugeboren	Independent Director	less than a year	US$53.00k	0.37% $ 114.1k
A. Davis	Independent Director	less than a year	US$57.50k	0% $ 0
Vimal Kavuru	Independent Chairman	3.2yrs	US$127.43k	15.92% $ 4.9m
S. Kottayil	Director	less than a year	US$44.90k	3.65% $ 1.1m
Andrew Ducruet	Member of Scientific Advisory Board	2.4yrs	geen gegevens	geen gegevens
Alex Choi	Member of Scientific Advisory Board	2.8yrs	geen gegevens	geen gegevens
W. Kimberly	Member of Scientific Advisory Board	1.3yrs	geen gegevens	geen gegevens
Alejandro Rabinstein	Member of Scientific Advisory Board	1.3yrs	geen gegevens	geen gegevens
Sherry Chou	Member of Scientific Advisory Board	1.3yrs	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ACST wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw bestuur.

Acasti Pharma Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Acasti Pharma Inc., Annual General Meeting, Sep 30, 2024

Acasti Pharma Inc. Approves Appointment of Robert J. Delaversano, as Principal Financial Officer and Principal Accounting Officer

Acasti Pharma Inc. Announces Board Changes

Independent Chairman recently bought US$1.2m worth of stock

Acasti Pharma Inc., Annual General Meeting, Sep 28, 2023

Acasti Pharma Inc. Announces Scientific Advisory Board Appointments

Recent updates

Acasti Pharma Inc. Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Acasti Pharma Inc., Annual General Meeting, Sep 30, 2024

Acasti Pharma Inc. Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-On Safety Trial

New major risk - Revenue and earnings growth

Acasti Pharma Inc. to Attend BIO International Convention 2024

We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

New major risk - Revenue and earnings growth

Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial

Acasti Pharma Inc. Approves Appointment of Robert J. Delaversano, as Principal Financial Officer and Principal Accounting Officer

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Acasti Pharma Inc. Announces Board Changes

Independent Chairman recently bought US$1.2m worth of stock

Acasti Pharma Inc. announced that it has received $7.499388 million in funding from S S Pharma Llc, Shore Pharma Llc

Acasti Pharma Inc., Annual General Meeting, Sep 28, 2023

New minor risk - Share price stability

Acasti Pharma Announces 1-For-6 Reverse Stock Split to Regain Compliance with the $1.00 Minimum Bid Price Continued Listing Requirement of the Nasdaq Capital Market

Acasti Pharma Inc. Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol

Acasti Pharma Inc. Announces Scientific Advisory Board Appointments

Forecast to breakeven in 2024

We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Second Quarter 2025

Acasti Pharma Inc. to Report Q3, 2023 Results on Feb 14, 2023

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma Inc. Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

Forecast to breakeven in 2024

High number of new and inexperienced directors

Acasti Pharma Inc. to Report Q2, 2023 Results on Nov 14, 2022

Acasti Pharma Inc. Announces Board Changes

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma GAAP EPS of -$0.10

Acasti Pharma Inc. to Report Q1, 2023 Results on Aug 11, 2022

Acasti Pharma Inc., Annual General Meeting, Sep 28, 2022

Acasti Pharma Inc. Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia

Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101

Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

Less than half of directors are independent

Less than half of directors are independent

Acasti Pharma Inc. Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104

Acasti Pharma Inc. Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, its Lead Drug Candidate for Treatment of Subarachnoid Hemorrhage

Acasti Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Insufficient new directors

Insufficient new directors

Acasti Pharma Inc. (TSXV:ACST) completed the acquisition of Grace Therapeutics, Inc.

Forecast breakeven pushed back to 2024

Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance

Acasti Pharma Inc. (TSXV:ACST) entered into a definitive agreement to acquire Grace Therapeutics, Inc. for $71.4 million.

Acasti inks deal for Grace Therapeutics, shares surge

Earnings miss expectations

New 90-day high: US$0.90

New 90-day high: US$0.57

New 90-day high: US$0.43

Acasti Pharma issues clarification on trading activity

New 90-day high: US$0.29

Acasti Pharma Inc. Announces Resignation of Brian Groch as Chief Commercial Officer, Effective December 31, 2020

Acasti Pharma EPS in-line

Acasti Pharma Inc. Announces Executive Changes

New 90-day low - US$0.24

Acasti Pharma Inc. Auditor Raises 'Going Concern' Doubt

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur